1195-34-2

Basic information

• Product Name: 4,6-DICHLORO-2-ETHYLPYRIMIDINE
• Synonyms: 4,6-DICHLORO-2-ETHYLPYRIMIDINE
• CAS NO: 1195-34-2
• Molecular Formula: C₆H₆Cl₂N₂
• Molecular Weight: 177.03
• Mol File: 1195-34-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 77 °C(Press: 5 Torr)
• Appearance: /
• Density: 1.2850 g/cm3(Temp: 25 °C)
• Storage Temp.: 2-8°C
• PKA: -3.74±0.30(Predicted)
• CAS DataBase Reference: 4,6-DICHLORO-2-ETHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLORO-2-ETHYLPYRIMIDINE(1195-34-2)
• EPA Substance Registry System: 4,6-DICHLORO-2-ETHYLPYRIMIDINE(1195-34-2)

Safety Data

• Hazardous Substances Data: 1195-34-2(Hazardous Substances Data)

Usage

General Description

4,6-Dichloro-2-ethylpyrimidine is a synthetic chemical compound with the molecular formula C6H6Cl2N2. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is a pale yellow to light brown liquid at room temperature and is insoluble in water but soluble in organic solvents. 4,6-Dichloro-2-ethylpyrimidine is considered to be a hazardous substance, with potential health hazards including skin and eye irritation. It is important to handle and store this chemical with proper care to avoid any potential risks to human health and the environment.

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 4489-34-3 4,6-dichloro-2-(methylsulfonyl)pyrimidine 
• 3709-98-6 2-ethylpyrimidine-4,6-diol 
• 7732-18-5 water 
• 857411-92-8 2-ethyl-1H-pyrimidine-4,6-dione 

Downstream Products

• 94415-35-7 4-chloro-2-ethyl-6-hydrazinylpyrimidine 

Relevant articles and documents

PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY

A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.

PYRIMIDINE PDE10 INHIBITORS

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrimidines substituted by nitrogen-containing heterocyclic rings as intermediates

1,2,4-Triazolo[4,3-c]pyrimidines substituted at the 5 or 7 position through a nitrogen atom which is part of a heterocyclic ring have been found to have potent bronchodilator activity and to be useful synthetic intermediates in the preparation of 1,2,4-triazolo[1,5-c]pyrimidines. Methods for inducing bronchodilation, pharmaceutical compositions, and synthetic processes and intermediates are also described.